Arcadia Biosciences Q3 2024 GAAP EPS $(1.18) Misses $(0.81) Estimate, Sales $1.537M Beat $1.399M Estimate

Benzinga11-13

Arcadia Biosciences (NASDAQ:RKDA) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(0.81) by 45.68 percent. The company reported quarterly sales of $1.537 million which beat the analyst consensus estimate of $1.399 million by 9.86 percent. This is a 3.76 percent decrease over sales of $1.597 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment